Stockscreener 앱 받기
25.43
0.32%
0.08
전일 마감가:
$25.35
열려 있는:
$25.37
하루 거래량:
1.23M
Relative Volume:
0.99
시가총액:
$1.94B
수익:
-
순이익/손실:
$-64.16M
주가수익비율:
-20.02
EPS:
-1.2702
순현금흐름:
$-69.06M
1주 성능:
+7.12%
1개월 성능:
+25.77%
6개월 성능:
-22.69%
1년 성능:
-17.89%
1일 변동 폭
$24.82
$25.73
1주일 범위
$23.32
$25.81
52주 변동 폭
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
명칭
Cg Oncology Inc
전화
(949) 419-6203
주소
400 SPECTRUM CENTER DRIVE, IRVINE
CGON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
25.43 | 1.81B | 0 | -64.16M | -69.06M | -1.2702 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | JP Morgan | Overweight |
| 2025-04-16 | 개시 | Scotiabank | Sector Perform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-23 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2024-06-28 | 개시 | BofA Securities | Buy |
| 2024-02-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-20 | 개시 | Goldman | Neutral |
| 2024-02-20 | 개시 | Morgan Stanley | Overweight |
| 2024-02-14 | 개시 | H.C. Wainwright | Buy |
모두보기
Cg Oncology Inc 주식(CGON)의 최신 뉴스
CG Oncology, Inc. (NASDAQ:CGON) Position Boosted by Northern Trust Corp - Defense World
Q2 Earnings Forecast for CG Oncology Issued By HC Wainwright - Defense World
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
Leading Bladder Cancer Drug Developer CG Oncology Takes Stage at Major RBC Healthcare Conference - Stock Titan
CG Oncology (NASDAQ:CGON) Shares Gap Down on Disappointing Earnings - Defense World
Decoding CG Oncology Inc (CGON): A Strategic SWOT Insight - GuruFocus
CG Oncology reports Q1 EPS (45c), consensus (37c) - TipRanks
CGON Q1 Revenue Falls Short; Advances in Bladder Cancer Therapy - GuruFocus
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - ADVFN
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
CG Oncology Q1 Loss Widens, Revenue Falls - marketscreener.com
CG Oncology, Inc. SEC 10-Q Report - TradingView
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Here Are Reasons Why Cg Oncology Inc (NASDAQ: CGON) Is A Great Choice Now - Stocksregister
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Target | CGON Stock News - GuruFocus
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Cg Oncology Inc’s (CGON) Stock Is Harder To Predict Than You Think - Stocksregister
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Wells Fargo & Company MN - Defense World
A look into Cg Oncology Inc (CGON)’s deeper side - Sete News
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Could Cg Oncology Inc (NASDAQ: CGON) Be The Biggest Winner? - Marketing Sentinel
Barclays PLC Acquires 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology's Bladder Cancer Drug Impresses InvestorsHere's Why - AOL.com
Cg Oncology Inc [CGON] Stock sold by Insider POST LEONARD E for $28000.0 - knoxdaily.com
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - MSN
TD Cowen Sticks to Its Buy Rating for CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Given Overweight Rating at Cantor Fitzgerald - Defense World
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
CG Oncology shares jump on positive clinical trial data for cancer drug - Mugglehead Magazine
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results - TipRanks
J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200 - insights.citeline.com
CG Oncology (CGON) Surges 25%: What Drove the Dramatic Stock Move? - Wealth Daily
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
CG Oncology’s Blistering Rally: What You Need to Know - RagingBull
Cantor Fitzgerald maintains CG Oncology stock with $75 target - Investing.com Australia
CG Oncology Reports Durable Responses for Cretostimogene in Bladder Cancer Treatment; Shares Rise - marketscreener.com
Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe - Endpoints News
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug - inkl
This Small Biotech Rival To J&J Just Rocketed 44% - Investor's Business Daily
Cantor Fitzgerald maintains CG Oncology stock with $75 target By Investing.com - Investing.com India
Cg Oncology Inc (CGON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):